Studies related to Pain and Type-II Collagen

A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort
Effect Decrease
Trial Design doubleblind
Trial Length 7months
Number of Subjects 207
Gender mixed
Notes for this study:
In patients with osteoarthritis given 10g hydrolyzed collagen over six months appeared to reduce pain assessed by VAS and WOMAC, although no other parameter on WOMAC (stiffness, function, or total score) was affected by treatment relative to placebo.
Funding issues for this study:
Funded by Colnatur, the producer of the collagen provided

Effects Of Oral Administration Of Type II Collagen On Rheumatoid Arthritis

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 60
Gender Both Genders
Age Range 65+
Notes for this study:
A study in 60 people with advanced rheumatoid arthritis given supplementation of solubilized collagen (0.1mg for one month then 1mg for the next) noted a reduction in joint pain and stiffness to a degree greater than placebo, with four subjects reporting resolution of symptoms dependent on supplementation (as symptoms reemerged after three months supplement cessation).

Safety And Efficacy Of Undenatured Type II Collagen In The Treatment Of Osteoarthritis Of The Knee: A Clinical Trial

Effect Decrease
Trial Design Cohort
Trial Length 1-6 months
Number of Subjects 52
Gender Both Genders
Age Range 45-64
Body Types Average
Notes for this study:
Supplementation of 40mg UC-II (undenatured CII) once daily for three months was able to improve symptoms of osteoarthritis as assessed by WOMAC, VAS, and Lequesne rating scales. The potency was comparable to a combination of glucosamine HCl (1,500mg) and chondroitin sulphate (1,200mg) on Lequesne and VAS, and more effective on WOMAC.

There was no placebo control used in this study and medication was relatively well tolerated.
Funding issues for this study:
Funded by InterHealth Research Center

Treatment Of Rheumatoid Arthritis With Oral Type II Collagen. Results Of A Multicenter, Double-blind, Placebo-controlled Trial

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 228
Gender Both Genders
Age Range 45-64
Notes for this study:
Supplementation of four doses of CII to rheumatic patients (20mcg, 100mcg, 500mcg, or 2.5mg) over 24 weeks noted that the lower doses were associated with higher response rates than the higher doses, with the 19% response seen in placebo being outperformed by a 39% response in the 20mcg group (25% response in 2.5mg was not statistically significant).

Response was determined by at least a 30% reduction in joint soreness with responses on ACR and the Paulus criteria, and when looking only at the 30% reduction in pain all treatment groups (excluding ACR and Paulus) performed somewhat equally.

IgA and IgG antibodies were detected only in a few subjects, and appeared to predict responsiveness to therapy at all doses despite their specificity to CII or overall amounts being affected.

Undenatured Type II Collagen (UC-II®) For Joint Support: A Randomized, Double-blind, Placebo-controlled Study In Healthy Volunteers

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 46
Gender Both Genders
Age Range 45-64
Body Types Overweight
Notes for this study:
40mg of undenatured CII daily for four months appeared to be able to increase joint mobility in subjects who reported non-pathological joint pain (no arthritic conditions) and both prolonged how long one could exercise before joint pain occurred while improving recovery speeds after exercise.

Despite the benefits during exercise, there was no overall reduction in joint pain as assessed by KOOS (a subjective rating scale). Supplementation was not associated with any adverse effects.
Funding issues for this study:
Grant from InterHealth Nutraceuticals with one author as consultant